Literature DB >> 9463679

Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs.

J C Allan1, M Velasquez-Tohom, C Fletes, R Torres-Alvarez, G Lopez-Virula, P Yurrita, H Soto de Alfaro, A Rivera, J Garcia-Noval.   

Abstract

Mass treatment of the human population with niclosamide was carried out in 2 villages in rural Guatemala where Taenia solium was endemic, to determine how this would affect the epidemiology of the parasite. Intestinal taeniasis was diagnosed by microscopy and coproantigen testing, and porcine cysticercosis by a specific Western blot. Before mass treatment, the prevalence of human taeniasis was 3.5%; 10 months after treatment it was 1%, a significant decrease (P < 10(-4)). All tapeworms that could be identified to the species level were T. solium. Similarly, the seroprevalence of antibodies to cysticercosis in pigs declined from 55% before treatment to 7% 10 months after treatment, once again a significant decrease (P < 10(-6)). These effects were seen in both villages. The possible use of mass chemotherapy as a tool in the control of T. solium is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463679     DOI: 10.1016/s0035-9203(97)90042-0

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  31 in total

Review 1.  Prevention and control of Taenia solium taeniasis/cysticercosis in Peru.

Authors:  Robert H Gilman; Armando E Gonzalez; Fernando Llanos-Zavalaga; Victor C W Tsang; Hector H Garcia
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

2.  Study and ranking of determinants of Taenia solium infections by classification tree models.

Authors:  Kabemba E Mwape; Isaac K Phiri; Nicolas Praet; Pierre Dorny; John B Muma; Gideon Zulu; Niko Speybroeck; Sarah Gabriël
Journal:  Am J Trop Med Hyg       Date:  2014-11-17       Impact factor: 2.345

3.  Barriers to Participation in a Community-Based Program to Control Transmission of Taenia solium in Peru.

Authors:  Michelle Beam; Angela Spencer; Lauralee Fernandez; Ruth Atto; Claudio Muro; Percy Vilchez; Ricardo Gamboa; Sandra Olaya; Viterbo Ayvar; Armando E Gonzalez; Hector H Garcia; Seth E O'Neal
Journal:  Am J Trop Med Hyg       Date:  2018-04-12       Impact factor: 2.345

4.  Magnitude of the disease burden from neurocysticercosis in a developing country.

Authors:  C Bern; H H Garcia; C Evans; A E Gonzalez; M Verastegui; V C Tsang; R H Gilman
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

5.  Neurocysticercosis.

Authors:  Pratibha Singhi
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

6.  Taenia solium taeniasis and cysticercosis control and elimination through community-based interventions.

Authors:  Hélène Carabin; Aminata A Traoré
Journal:  Curr Trop Med Rep       Date:  2014-12-01

Review 7.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

Review 8.  Taenia solium cysticercosis.

Authors:  Héctor H García; Armando E Gonzalez; Carlton A W Evans; Robert H Gilman
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

Review 9.  Management of neurocysticercosis.

Authors:  Terrence Riley; A C White
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Elimination of Taenia solium Transmission in Northern Peru.

Authors:  Hector H Garcia; Armando E Gonzalez; Victor C W Tsang; Seth E O'Neal; Fernando Llanos-Zavalaga; Guillermo Gonzalvez; Jaime Romero; Silvia Rodriguez; Luz M Moyano; Viterbo Ayvar; Andre Diaz; Allen Hightower; Philip S Craig; Marshall W Lightowlers; Charles G Gauci; Elli Leontsini; Robert H Gilman
Journal:  N Engl J Med       Date:  2016-06-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.